Get access

Clinical outcomes for rectal carcinoid tumors according to a new (AJCC 7th edition) TNM staging system: A single institutional analysis of 122 patients

Authors

  • Min Sung Kim MD,

    1. Section of Colon and Rectal Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea
    Search for more papers by this author
  • Hyuk Hur MD,

    1. Section of Colon and Rectal Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea
    Search for more papers by this author
  • Byung Soh Min MD,

    1. Section of Colon and Rectal Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea
    Search for more papers by this author
  • Seung Hyuk Baik MD, PhD,

    1. Section of Colon and Rectal Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea
    Search for more papers by this author
  • Kang Young Lee MD, PhD,

    1. Section of Colon and Rectal Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea
    Search for more papers by this author
  • Nam Kyu Kim MD, PhD

    Corresponding author
    1. Section of Colon and Rectal Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea
    • Section of Colon and Rectal Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, South Korea. Fax: +82-2-313-8289.

    Search for more papers by this author

  • The authors have nothing to disclose.

Abstract

Background and Objectives

This study aimed to describe clinical outcomes of rectal carcinoids according to the 7th American Joint Council on Cancer (AJCC) TNM staging system.

Methods

We retrospectively reviewed 122 patients who were treated for rectal carcinoids between 1995 and 2010.

Results

Among 122 patients, 81.2% (n = 99) were classified as stage I, 4.9% (n = 6) as stage II, 11.5% (n = 14) as stage III, and 2.5% (n = 3) as stage IV. Lymph node (LN) metastasis rates for pT1a, 1b, 2, and 3 stages were 1.2% (1/85), 16.7% (3/18), 0% (0/4) and 84.6% (11/13), respectively. The 5-year overall survival (OS) rate was 88.4%. The 5-year OS rates were estimated to be 100%, 80%, 51.4% and 0% for stage I, II, III, and IV, respectively (P < 0.001). The 5-year disease-free survival (DFS) rate was 82.3%. The 5-year DFS rates were estimated to be 97.7%, 62.5%, 17.1%, and 0% for stages I, II, III, and IV, respectively (P < 0.001).

Conclusions

Using the new TNM stage, we confirmed a prognostic difference in LN metastasis rates, OS, and DFS for rectal carcinoids. In clinical practice, the new TNM stage can be very useful for predicting prognosis. J. Surg. Oncol. 2013;107:835–841. © 2013 Wiley Periodicals, Inc.

Ancillary